Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when IMVT files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: IMVT Immunovant, Inc. 8-K

Immunovant reports Q4 and fiscal year 2026 financial results

Filed May 20, 2026 · Period ending May 20, 2026 · ~1 min read

2 key changes 1 section

Key Changes

  • medium

    Company issued press release announcing financial results for fourth quarter and full fiscal year ended March 31, 2026. Actual figures are in the attached exhibit, not the 8-K body.

    Item 2.02 verify on EDGAR →
  • low

    This is a routine earnings announcement filing. The 8-K itself contains no financial data—investors must review the press release exhibit for performance details.

    8-K: Earnings view on EDGAR →

Summary

Immunovant filed an 8-K to announce its fourth quarter and fiscal year 2026 financial results, covering the period ended March 31, 2026. This is a standard quarterly earnings disclosure required by SEC rules. The filing itself is procedural and does not include the actual financial figures or operational updates—those details are contained in the attached press release (Exhibit 99.1).

Retail investors should review the press release exhibit directly to understand the company's financial performance, cash position, and any forward-looking guidance. As a biotech company, key metrics to watch include cash runway, R&D spending, and progress on clinical trials. The next quarterly report will provide an update on how the company is executing against its pipeline milestones and managing its capital resources.

Section-by-Section Diff

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

Immunovant filed an 8-K attaching a press release dated May 20, 2026; no material business event disclosed in the filing body.

1 Added
Show 1 minor / wording change
Added Press release attachment low

Added in current filing · verify on EDGAR →

Press release, dated May 20, 2026.

The 8-K references an attached press release dated May 20, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the press release content, making this a procedural filing. Investors should review Exhibit 99.1 directly to understand what was announced.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify